This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ensign Group (ENSG) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Ensign Group (ENSG) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Humana Incurs Wider Y/Y Loss in Q4 on Decline in Membership
by Zacks Equity Research
HUM's fourth-quarter results suffer a blow due to a membership decline in Medicare stand-alone PDP, partly offset by a strong Primary Care business. It currently expects 2025 adjusted EPS to be around $16.25.
Can Tenet Healthcare Navigate Through Lower Revenues in Q4?
by Zacks Equity Research
THC's fourth-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Ensign Group Shares Plunge 12% Despite Q4 Earnings Beat
by Zacks Equity Research
ENSG's fourth-quarter results gain on strong contribution from the Skilled Services unit, partly offset by the escalating cost of services. It estimates 2025 adjusted EPS to be within $6.16-$6.34.
Wall Street Analysts Believe Ensign Group (ENSG) Could Rally 26.08%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 26.1% upside potential for Ensign Group (ENSG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Ensign Group (ENSG) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is The Ensign Group (ENSG) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.36% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights BioMarin, Cheesecake Factory, Leidos and The Ensign
by Zacks Equity Research
BioMarin, Cheesecake Factory, Leidos and The Ensign have been highlighted in this Screen of The Week article.
4 Stocks That Sport Impressive Interest Coverage Ratio
by Sumit Singh
BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ensign Group (ENSG) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Ensign Group (ENSG) possesses solid growth attributes, which could help it handily outperform the market.
Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights include BioMarin, Amazon.com, Leidos and The Ensign
by Zacks Equity Research
BioMarin, Amazon.com, Leidos and The Ensign have been highlighted in this Screen of The Week article.
These 4 Stocks Boast Impressive Interest Coverage Ratio
by Sumit Singh
BMRN, AMZN, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Here's Why You Should Add Ensign Stock to Your Portfolio Now
by Zacks Equity Research
ENSG's valuation looks relatively cheap compared with the industry average.
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
by Zacks Equity Research
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
The Zacks Analyst Blog Highlights Ensign, Cardinal Health, Atmos Energy and IDACORP
by Zacks Equity Research
Ensign, Cardinal Health, Atmos Energy and IDACORP are included in this Analyst Blog.
Consumer Sentiment Declines Amid Rate Cut Uncertainty: 4 Safe Bets
by Ritujay Ghosh
Low-beta defensive stocks like ENSG, CAH, ATO and IDA are a safe bet during times of market volatility.
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compelling Reasons for Investors to Hold on to Centene Stock
by Zacks Equity Research
CNC remains well-poised for growth on the back of an expanding customer base, improved premiums, strategic acquisitions and commendable cash reserves.
Ensign Group Bolsters Healthcare Portfolio With Nine New Facilities
by Zacks Equity Research
ENSG acquires operations of nine skilled nursing facilities, marking its debut in Alabama and strengthening its Tennessee footprint, to enhance care and grow its Skilled Services segment.
3 Reasons Growth Investors Will Love Ensign Group (ENSG)
by Zacks Equity Research
Ensign Group (ENSG) possesses solid growth attributes, which could help it handily outperform the market.
Should You Buy, Sell or Hold Pediatrix Medical Stock at a 9.28X P/E?
by Zacks Equity Research
Stable same-facility patient volume growth, inorganic initiatives and transition to an RCM structure should aid MD's future growth.